SEC Form 8-K Summary
Registrant: Vallon Pharmaceuticals, Inc. (now associated with the proposed merger with GRI Bio, Inc.; the filing itself identifies Vallon as the registrant)
Report date: February 28, 2023; signed March 2, 2023
Business Context and Reporting Period
The filing reports an additional Nasdaq deficiency related to stockholders’ equity and provides an update on the Company’s pending delisting proceedings, proposed merger with GRI Bio, Inc., and related reverse stock split. The referenced financial information is from the Company’s Form 10-K for the year ended December 31, 2022.
Key Financial and Listing Metrics
- Stockholders’ equity as of December 31, 2022: $2.342 million.
- Nasdaq Capital Market minimum stockholders’ equity requirement: $2.5 million.
- The Company did not satisfy the alternative continued-listing standards based on market value of listed securities or net income from continuing operations.
- The filing does not provide revenue, net income, cash flow, cash balance, debt, liquidity, or margin figures.
Material Changes and Nasdaq Status
- On February 28, 2023, Nasdaq notified the Company that it no longer complied with Nasdaq Listing Rule 5550(b), creating an additional basis for potential delisting.
- The notice had no immediate effect on the Nasdaq listing of the Company’s common stock.
- The Company previously received a deficiency notice for failing to maintain a minimum $1.00 bid price. Nasdaq’s delisting process was stayed pending a hearing.
- Following a February 16, 2023 hearing, the Nasdaq Hearings Panel granted a stay of delisting procedures through April 28, 2023, subject to conditions including completion of the proposed merger and satisfaction of all initial Nasdaq listing requirements by that date.
Outlook, Risks, and Unusual Items
Management communicated to Nasdaq that it expects to close the merger on or before April 28, 2023 and expects to demonstrate compliance with initial listing requirements, including the stockholders’ equity requirement. The Company stated that it does not expect delisting unless the merger is not completed by that date.
There can be no assurance that the merger will close by April 28, 2023 or at all, that the Company will satisfy initial or continuing Nasdaq requirements, or that it will maintain compliance with other listing standards. Additional risks include costs and management distraction related to the merger and Nasdaq proceedings, as well as potential difficulty curing listing deficiencies.
Investor Verification Priorities
- Verify completion status and terms of the proposed Vallon-GRI Bio merger and any related reverse stock split.
- Confirm whether the Company satisfied Nasdaq’s initial listing requirements by April 28, 2023.
- Review updated stockholders’ equity, capitalization, cash resources, financing needs, and any subsequent delisting or listing determinations.
- Assess the risk that the merger is delayed or terminated and the resulting effect on Nasdaq listing status.
- Review subsequent SEC filings for changes in corporate name, ticker symbol, ownership, and post-merger financial condition.